Japan’s move to conditionally approve two induced pluripotent stem cell derived therapies marks a significant development for ...
Anavex Life Sciences Corp. (NASDAQ:AVXL) has withdrawn its application for European Union marketing authorization for ...
The company is acknowledged for its scalable technology platform, application diversity, and customer-centered ...
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim ...
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in ear ...
Metabolic engineering, critical in modern biotechnology, focuses on employing microbial systems to produce valuable bioactive ...
There are three technical enablers “that repeatedly separate successful [AI] deployments from stalled pilots: trustworthy data pipelines, fit-for-purpose model selection, and lifestyle governance,” ...
XCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results